University of Houston upgrades to contactless market technology

new to campus

Contact-free market shopping has come to campus at UH. Photo courtesy of UH

A convenience store on campus at the University of Houston just got a little more, well, convenient — and a whole lot safer.

UH and its dining services partner, Chartwells Higher Education, have partnered with tech company Standard to upgrade the check-out process of convenience shopping. The technology is easy to install and can retrofit any convenience store to a contact-less process.

"Students' tastes change constantly, and we're well equipped to handle that. But their shopping preferences evolve too, and we want to continue providing new and unique shopping experiences that are unexpected on a college campus," says David Riddle, vice president of operations for Chartwells Higher Ed, and district manager for UH System Dining, in a press release. "This is the future of shopping, and with autonomous checkout through Standard, we've made it as easy, safe and convenient as possible for students to come in, get what they need, and go."

The store, called Market Next, is located at UH's Technology Bridge and opened earlier this month. Enabled by cameras and easy-to-use scanners, the store operates 24 hours a day and is also designed for quick service for students on the go. The fastest shopping trip recorded by Standard is 2.3 seconds.

"Market Next is the first retail store in the world to be retrofitted for a 100 percent cashierless, checkout-free experience," says Jordan Fisher, co-founder and CEO of Standard, in the release. "Our platform is the only system on the market proven to retrofit an entire retail experience. Innovative retailers like Chartwells use the AI-powered Standard platform to enable shoppers to grab any product they want and simply walk out, without waiting in line. We are excited to partner with Chartwells to deliver this groundbreaking technology to more locations around the country."

Chartwells is working with Standard to bring more of these stores across the country — as well as more itterations on the UH campus.

"Checkout-free technology is an innovation that will make our students' lives a little easier and a lot safer. This is the new standard for campus safety that is important to students today and for the foreseeable future," says Emily Messa, associate vice chancellor and associate vice president for administration at UH, in the release. "That's why we will plan to convert additional Market stores on campus to this technology in the coming year."

The University of Houston campus has 30 new members — self-driving, food-delivering robots. Photo courtesy of UH

University of Houston rolls out food delivery robots

on the move

For a small delivery fee of $1.99, students, faculty, and staff across the University of Houston campus can now get their lunch delivered by self-driving robots.

Thirty of San Francisco-based Starship Technologies' autonomous delivery robots now roam the campus thanks to a partnership with New York-based Chartwells Higher Education. The Houston campus is the first to roll out robotic food deliveries.

"This revolutionary delivery method will make it more convenient for the campus community to take advantage of our diverse dining program from anywhere on campus while expanding the hours of operation," says Emily Messa, associate vice president for administration, in a news release. "By opening our campus to this innovative service, which is paid for by the customers, the university didn't have to spend any money purchasing the technology, yet we're enhancing our food delivery capabilities."

Through the Starship Deliveries app, which is available on iOS and Android, users can select from 11 dining institutions and then identify where they are on campus. The platform allows the user to track the progress, and the device can hold up to 20 lbs of food and has the space for about three shopping bags of groceries.

"This increases our capacity to reach more customers, and I expect the robots will quickly become part of campus life," says David Riddle, Chartwells resident district manager, in a news release. (Chartwells manages UH Dining). "Robot delivery will also grow opportunities for UH Dining employees by increasing service hours and growing sales. It has also created additional jobs for students dedicated specifically to servicing the autonomous robots. It's an important advancement for foodservice at UH."

Using machine learning, artificial intelligence and sensors, the company's robots have driven over 350,000 miles and completed over 150,000 deliveries. The Starship robots "can cross streets, climb curbs, travel at night and operate in both rain and snow," per the release.

"Robotic delivery is affordable, convenient and environmentally friendly," says Ryan Tuohy, senior vice president of business development for Starship, in the release. "We're excited to start offering students, staff and faculty at Houston delivery within minutes when they need it most."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Greentown Labs names Lawson Gow as its new Houston leader

head of hou

Greentown Labs has named Lawson Gow as its Head of Houston.

Gow is the founder of The Cannon, a coworking space with seven locations in the Houston area, with additional partner spaces. He also recently served as managing partner at Houston-based investment and advisory firm Helium Capital. Gow is the son of David Gow, founder of Energy Capital's parent company, Gow Media.

According to Greentown, Gow will "enhance the founder experience, cultivate strategic partnerships, and accelerate climatetech solutions" in his new role.

“I couldn’t be more excited to join Greentown at this critical moment for the energy transition,” Gow said in a news release. “Greentown has a fantastic track record of supporting entrepreneurs in Houston, Boston, and beyond, and I am eager to keep advancing our mission in the energy transition capital of the world.”

Gow has also held analyst, strategy and advising roles since graduating from Rice University.

“We are thrilled to welcome Lawson to our leadership team,” Georgina Campbell Flatter, CEO of Greentown Labs, added in the release. “Lawson has spent his career building community and championing entrepreneurs, and we look forward to him deepening Greentown’s support of climate and energy startups as our Head of Houston.”

Gow is the latest addition to a series of new hires at Greentown Labs following a leadership shakeup.

Flatter was named as the organization's new CEO in February, replacing Kevin Dutt, Greentown’s interim CEO, who replaced Kevin Knobloch after he announced that he would step down in July 2024 after less than a year in the role.

Greentown also named Naheed Malik its new CFO in January.

Timmeko Moore Love was named the first Houston general manager and senior vice president of Greentown Labs. According to LinkedIn, she left the role in January.

---

This article originally appeared on our sister site, EnergyCapitalHTX.com.

Houston foundation grants $27M to support Texas chemistry research

fresh funding

Houston-based The Welch Foundation has doled out $27 million in its latest round of grants for chemical research, equipment and postdoctoral fellowships.

According to a June announcement, $25.5 million was allocated for the foundation's longstanding research grants, which provide $100,000 per year in funding for three years to full-time, regular tenure or tenure-track faculty members in Texas. The foundation made 85 grants to faculty at 16 Texas institutions for 2025, including:

  • Michael I. Jacobs, assistant professor in the chemistry and biochemistry department at Texas State University, who is investigating the structure and thermodynamics of intrinsically disordered proteins, which could "reveal clues about how life began," according to the foundation.
  • Kendra K. Frederick, assistant professor in the biophysics department at The University of Texas Southwestern Medical Center, who is studying a protein linked to Parkinson’s disease.
  • Jennifer S. Brodbelt, professor in chemistry at The University of Texas at Austin, who is testing a theory called full replica symmetry breaking (fullRSB) on glass-like materials, which has implications for complex systems in physics, chemistry and biology.

Additional funding will be allocated to the Welch Postdoctoral Fellows of the Life Sciences Research Foundation. The program provides three-year fellowships to recent PhD graduates to support clinical research careers in Texas. Two fellows from Rice University and Baylor University will receive $100,000 annually for three years.

The Welch Foundation also issued $975,000 through its equipment grant program to 13 institutions to help them develop "richer laboratory experience(s)." The universities matched funds of $352,346.

Since 1954, the Welch Foundation has contributed over $1.1 billion for Texas-nurtured advancements in chemistry through research grants, endowed chairs and other chemistry-related ventures. Last year, the foundation granted more than $40.5 million in academic research grants, equipment grants and fellowships.

“Through funding basic chemical research, we are actively investing in the future of humankind,” Adam Kuspa, president of The Welch Foundation, said the news release. “We are proud to support so many talented researchers across Texas and continue to be inspired by the important work they complete every day.”

New Houston biotech co. developing capsules for hard-to-treat tumors

biotech breakthroughs

Houston company Sentinel BioTherapeutics has made promising headway in cancer immunotherapy for patients who don’t respond positively to more traditional treatments. New biotech venture creation studio RBL LLC (pronounced “rebel”) recently debuted the company at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.

Rima Chakrabarti is a neurologist by training. Though she says she’s “passionate about treating the brain,” her greatest fervor currently lies in leading Sentinel as its CEO. Sentinel is RBL’s first clinical venture, and Chakrabarti also serves as cofounder and managing partner of the venture studio.

The team sees an opportunity to use cytokine interleukin-2 (IL-2) capsules to fight many solid tumors for which immunotherapy hasn't been effective in the past. “We plan to develop a pipeline of drugs that way,” Chakrabarti says.

This may all sound brand-new, but Sentinel’s research goes back years to the work of Omid Veiseh, director of the Rice Biotechnology Launch Pad (RBLP). Through another, now-defunct company called Avenge Bio, Veiseh and Paul Wotton — also with RBLP and now RBL’s CEO and chairman of Sentinel — invested close to $45 million in capital toward their promising discovery.

From preclinical data on studies in mice, Avenge was able to manufacture its platform focused on ovarian cancer treatments and test it on 14 human patients. “That's essentially opened the door to understanding the clinical efficacy of this drug as well as it's brought this to the attention of the FDA, such that now we're able to continue that conversation,” says Chakrabarti. She emphasizes the point that Avenge’s demise was not due to the science, but to the company's unsuccessful outsourcing to a Massachusetts management team.

“They hadn't analyzed a lot of the data that we got access to upon the acquisition,” explains Chakrabarti. “When we analyzed the data, we saw this dose-dependent immune activation, very specific upregulation of checkpoints on T cells. We came to understand how effective this agent could be as an immune priming agent in a way that Avenge Bio hadn't been developing this drug.”

Chakrabarti says that Sentinel’s phase II trials are coming soon. They’ll continue their previous work with ovarian cancer, but Chakrabarti says that she also believes that the IL-2 capsules will be effective in the treatment of endometrial cancer. There’s also potential for people with other cancers located in the peritoneal cavity, such as colorectal cancer, gastrointestinal cancer and even primary peritoneal carcinomatosis.

“We're delivering these capsules into the peritoneal cavity and seeing both the safety as well as the immune activation,” Chakrabarti says. “We're seeing that up-regulation of the checkpoint that I mentioned. We're seeing a strong safety signal. This drug was very well-tolerated by patients where IL-2 has always had a challenge in being a well-tolerated drug.”

When phase II will take place is up to the success of Sentinel’s fundraising push. What we do know is that it will be led by Amir Jazaeri at MD Anderson Cancer Center. Part of the goal this summer is also to create an automated cell manufacturing process and prove that Sentinel can store its product long-term.

“This isn’t just another cell therapy,” Chakrabarti says.

"Sentinel's cytokine factory platform is the breakthrough technology that we believe has the potential to define the next era of cancer treatment," adds Wotton.

View All Listings